Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales. Moderna’s earnings per share and revenue surpassed Wall Street expectations, with earnings reaching a surprising profit and revenue exceeding projected figures. Moderna’s new RSV vaccine added $10 million in U.S. sales. The company reiterated its 2024 outlook. Moderna plans further expense reductions, targeting $1 billion in savings by 2027. Shares remain down nearly 50% for the year.
Category
🗞
NewsTranscript
00:00It's Benzinga bringing Wall Street to Main Street.
00:02Moderna posted a surprising third quarter profit driven by cost cutting and higher than expected
00:07COVID vaccine sales. Moderna's earnings per share in revenue both surpassed Wall Street
00:12expectations, with earnings reaching a surprising profit and revenue exceeding projected figures.
00:17Moderna's new RSV vaccine added $10 million in U.S. sales. The company reiterated its 2024
00:24outlook. Moderna plans further expense reductions targeting $1 billion in savings by 2027.
00:31Shares remain down nearly 50% for the year. For all things money, visit Benzinga.com slash GSTV.